Earnings Per Share, Basic of Adaptimmune Therapeutics PLC from 30 Sep 2018 to 30 Jun 2025
- Taxonomy & unit
- us-gaap: USD/shares
- Description
- The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
- Summary
-
Adaptimmune Therapeutics PLC quarterly and annual Earnings Per Share, Basic in USD/shares history and change rate from 30 Sep 2018 to 30 Jun 2025.
- Adaptimmune Therapeutics PLC Earnings Per Share, Basic for the quarter ending 30 Jun 2025 was -0.02, a 140% decline year-over-year.
- Adaptimmune Therapeutics PLC Earnings Per Share, Basic for the twelve months ending 30 Jun 2025 was 0, a 140% decline year-over-year.
- Adaptimmune Therapeutics PLC annual Earnings Per Share, Basic for 2024 was -0.05, a 44% increase from 2023.
- Adaptimmune Therapeutics PLC annual Earnings Per Share, Basic for 2023 was -0.09, a 47% increase from 2022.
- Adaptimmune Therapeutics PLC annual Earnings Per Share, Basic for 2022 was -0.17, unchanged from 2021.
- Source SEC data
- View on sec.gov
Earnings Per Share, Basic, Trailing 12 Months (USD/shares)
Earnings Per Share, Basic, Quarterly (USD/shares)
Earnings Per Share, Basic, YoY Quarterly Change (%)
Earnings Per Share, Basic, Annual (USD/shares)
Earnings Per Share, Basic, YoY Annual Change (%)
Adaptimmune Therapeutics PLC Quarterly Earnings Per Share, Basic (USD/shares)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2025 | 0 | -0.02 | -0.07 | -140% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 13 Aug 2025 | 2025 | Q2 |
| Q1 2025 | 0 | -0.03 | 0 | 0% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 13 May 2025 | 2025 | Q1 |
| Q4 2024 | 0 | -0.06 | -0.02 | -50% | 01 Oct 2024 | 31 Dec 2024 | 10-K | 24 Mar 2025 | 2024 | FY |
| Q3 2024 | 0 | -0.01 | +0.02 | +67% | 01 Jul 2024 | 30 Sep 2024 | 10-Q | 13 Nov 2024 | 2024 | Q3 |
| Q2 2024 | 0 | 0.05 | +0.07 | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 13 Aug 2025 | 2025 | Q2 | |
| Q1 2024 | 0 | -0.03 | -0.03 | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 13 May 2025 | 2025 | Q1 | |
| Q4 2023 | 0 | -0.04 | -0.01 | -33% | 01 Oct 2023 | 31 Dec 2023 | 10-K | 24 Mar 2025 | 2024 | FY |
| Q3 2023 | 0 | -0.03 | +0.01 | +25% | 01 Jul 2023 | 30 Sep 2023 | 10-Q | 13 Nov 2024 | 2024 | Q3 |
| Q2 2023 | 0 | -0.02 | +0.03 | +60% | 01 Apr 2023 | 30 Jun 2023 | 10-Q | 12 Aug 2024 | 2024 | Q2 |
| Q1 2023 | 0 | 0 | +0.05 | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 15 May 2024 | 2024 | Q1 | |
| Q4 2022 | 0 | -0.03 | +0.01 | +25% | 01 Oct 2022 | 31 Dec 2022 | 10-K | 24 Mar 2025 | 2024 | FY |
| Q3 2022 | 0 | -0.04 | +0.01 | +20% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 08 Nov 2023 | 2023 | Q3 |
| Q2 2022 | 0 | -0.05 | -0.01 | -25% | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 09 Aug 2023 | 2023 | Q2 |
| Q1 2022 | 0 | -0.05 | -0.01 | -25% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 12 May 2023 | 2023 | Q1 |
| Q4 2021 | 0 | -0.04 | 01 Oct 2021 | 31 Dec 2021 | 10-K | 06 Mar 2024 | 2023 | FY | ||
| Q3 2021 | -0.05 | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 08 Nov 2022 | 2022 | Q3 | |||
| Q2 2021 | -0.04 | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 04 Aug 2022 | 2022 | Q2 | |||
| Q1 2021 | -0.04 | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 09 May 2022 | 2022 | Q1 | |||
| Q3 2019 | -0.06 | -0.07 | -700% | 01 Jul 2019 | 30 Sep 2019 | 10-Q | 06 Nov 2019 | 2019 | Q3 | |
| Q3 2018 | 0.01 | 01 Jul 2018 | 30 Sep 2018 | 10-Q | 06 Nov 2019 | 2019 | Q3 |
Adaptimmune Therapeutics PLC Annual Earnings Per Share, Basic (USD/shares)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2024 | -0.05 | +0.04 | +44% | 01 Jan 2024 | 31 Dec 2024 | 10-K | 24 Mar 2025 | 2024 | FY |
| 2023 | -0.09 | +0.08 | +47% | 01 Jan 2023 | 31 Dec 2023 | 10-K | 24 Mar 2025 | 2024 | FY |
| 2022 | -0.17 | 0 | 0% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 24 Mar 2025 | 2024 | FY |
| 2021 | -0.17 | -0.02 | -13% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 06 Mar 2024 | 2023 | FY |
| 2020 | -0.15 | +0.07 | +32% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 06 Mar 2023 | 2022 | FY |
| 2019 | -0.22 | 01 Jan 2019 | 31 Dec 2019 | 10-K | 14 Mar 2022 | 2021 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.